Difference between revisions of "Team:Tongji China/Description"

(Prototype team page)
 
Line 1: Line 1:
−
{{Tongji_China}}
+
{{Tongji_China/Head_N_Prefix}}
 
<html>
 
<html>
 +
<link rel="stylesheet" type="text/css" href="https://2018.igem.org/Template:Tongji_China/userDefault?action=raw&ctype=text/css">
 +
</html>
 +
{{Tongji_China/Head_N_Suffix}}
 +
{{Tongji_China/Header_N}}
 +
<html>
 +
<head>
 +
<meta charset="UTF-8">
 +
<title>Description</title>
 +
</head>
 +
<body>
 +
<div class="title">
 +
Project
 +
</div>
 +
<div class="logoPicture">
 +
<img src="https://static.igem.org/mediawiki/2018/5/55/T--Tongji_China--picture-Project-Description-0.png" width="30%" height="50%">
 +
</div>
 +
<div class="title_2">
 +
Description
 +
</div>
 +
<div class="content">
 +
This page will give you an overview of our project. The whole process is shown below and following the detailed description.
 +
<br>
 +
<div class="titleInContent">Introduction</div>
 +
As is shown above, neoantigens have already shown the promising potential in Individualized cancer treatment. (See more details about neoantigens, visit the background-neoantigens). And as we find the efficient protein delivery tool of Type III secretion system(T3SS) in P.A., (See more details about T3SS, visit the background-T3SS), We establish a method which can deliver neoantigens into the immune system using the Type III secretion system of Pseudomonas aeruginosa. We select colorectal cancer as our target and use the bioinformatics method to filter our item antigens. Then we use the T3SS to deliver the item antigens into the immune system through oral intake of engineered attenuated bacteria.
 +
<br>
 +
<img src="https://static.igem.org/mediawiki/2018/7/70/T--Tongji_China--picture-Project-Description-1.png" width="90%">
 +
<br>
 +
<font color="#BC818D" size="5"><b>1</b></font> We utilize the data resources from TCGA, which contains cancer cells’ SNVs(single nucleotide variations) from many kinds of cancers. We establish a program to filter the antigens we want from these data. What we need to do
 +
<br><br>
 +
<font color="#BC818D" size="5"><b>2</b></font> Antigen sequences which have been filtered will be combined with the Type III secretion system in the attenuated P.A. and form the engineered P.A.. The engineered P.A. are made into enteric capsule after lyophilization.
 +
<br><br>
 +
<font color="#BC818D" size="5"><b>3</b></font> Through orally intake the enteric capsule, the capsule goes into the intestine and releases the engineered P.A. Because the intestine possess its own immune system and there are many interstitial cells including APCs (antigen presenting cells). The engineered P.A. can attach the APCs which are our target cells.
 +
<br><br>
 +
<font color="#BC818D" size="5"><b>4</b></font> The attachment of the engineered P.A. and the APCs will trigger the formation of the Type III secretion system injectisome which is colored as red and also trigger the expression of the fusion protein. The fusion protein contains the antigens we filtered above and a T3SS effector or secretion signal and they will go through the injectisome and enter the APCs cytosol. Through this process, the antigens will be successfully injected into the APCs to start the MHC I antigen presenting pathway without being interrupted by the complicated intestine environment.
 +
<br><br>
 +
<font color="#BC818D" size="5"><b>5</b></font> Through the MHC I antigen presenting pathway, the antigens are presented on the APCs membrane for the recognition of the T cells. The T cells recognize and are activated by the antigens through the TCR binds to the presented antigens
 +
<br><br>
 +
<font color="#BC818D" size="5"><b>6</b></font> As the T cells are activated by the antigens, they will have the ability to recognize and kill the tumor cells.
  
−
 
+
</div>
−
 
+
−
<div class="column full_size">
+
</body>
−
<h1>Description</h1>
+
−
 
+
−
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
+
−
 
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
<div class="column two_thirds_size">
+
−
<h3>What should this page contain?</h3>
+
−
<ul>
+
−
<li> A clear and concise description of your project.</li>
+
−
<li>A detailed explanation of why your team chose to work on this particular project.</li>
+
−
<li>References and sources to document your research.</li>
+
−
<li>Use illustrations and other visual resources to explain your project.</li>
+
−
</ul>
+
−
</div>
+
−
 
+
−
<div class="column third_size" >
+
−
<div class="highlight decoration_A_full">
+
−
<h3>Inspiration</h3>
+
−
<p>See how other teams have described and presented their projects: </p>
+
−
 
+
−
<ul>
+
−
<li><a href="https://2016.igem.org/Team:Imperial_College/Description">2016 Imperial College</a></li>
+
−
<li><a href="https://2016.igem.org/Team:Wageningen_UR/Description">2016 Wageningen UR</a></li>
+
−
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> 2014 UC Davis</a></li>
+
−
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">2014 SYSU Software</a></li>
+
−
</ul>
+
−
</div>
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
 
+
−
<div class="column two_thirds_size" >
+
−
<h3>Advice on writing your Project Description</h3>
+
−
 
+
−
<p>
+
−
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be concise, accurate, and unambiguous in your achievements.
+
−
</p>
+
−
 
+
−
</div>
+
−
 
+
−
<div class="column third_size">
+
−
<h3>References</h3>
+
−
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
+
−
 
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
 
</html>
 
</html>

Revision as of 09:34, 5 October 2018

Description
Project
Description
This page will give you an overview of our project. The whole process is shown below and following the detailed description.
Introduction
As is shown above, neoantigens have already shown the promising potential in Individualized cancer treatment. (See more details about neoantigens, visit the background-neoantigens). And as we find the efficient protein delivery tool of Type III secretion system(T3SS) in P.A., (See more details about T3SS, visit the background-T3SS), We establish a method which can deliver neoantigens into the immune system using the Type III secretion system of Pseudomonas aeruginosa. We select colorectal cancer as our target and use the bioinformatics method to filter our item antigens. Then we use the T3SS to deliver the item antigens into the immune system through oral intake of engineered attenuated bacteria.

1 We utilize the data resources from TCGA, which contains cancer cells’ SNVs(single nucleotide variations) from many kinds of cancers. We establish a program to filter the antigens we want from these data. What we need to do

2 Antigen sequences which have been filtered will be combined with the Type III secretion system in the attenuated P.A. and form the engineered P.A.. The engineered P.A. are made into enteric capsule after lyophilization.

3 Through orally intake the enteric capsule, the capsule goes into the intestine and releases the engineered P.A. Because the intestine possess its own immune system and there are many interstitial cells including APCs (antigen presenting cells). The engineered P.A. can attach the APCs which are our target cells.

4 The attachment of the engineered P.A. and the APCs will trigger the formation of the Type III secretion system injectisome which is colored as red and also trigger the expression of the fusion protein. The fusion protein contains the antigens we filtered above and a T3SS effector or secretion signal and they will go through the injectisome and enter the APCs cytosol. Through this process, the antigens will be successfully injected into the APCs to start the MHC I antigen presenting pathway without being interrupted by the complicated intestine environment.

5 Through the MHC I antigen presenting pathway, the antigens are presented on the APCs membrane for the recognition of the T cells. The T cells recognize and are activated by the antigens through the TCR binds to the presented antigens

6 As the T cells are activated by the antigens, they will have the ability to recognize and kill the tumor cells.